Sales of GlaxoSmithKline PLC’s oral care brand Sensodyne lead Consumer Healthcare sales with 2% growth in the second quarter to $1.99 billion. The company reported July 24 that oral care sales were up 8% to $736.6 million, with sales of the Sensodyne Sensitivity and Acid Erosion up 19% in the April-June period. This was offset by a 9% decline in sales of Aquafresh. Consumer Healthcare overall sales grew 5% in the first half of 2013, excluding non-core OTC brands that in the first half of 2012. The firm also sold off 19 international brands to Aspen Pharmacare Holdings Ltd. in 2012 for $263 million Also see "Only Alli Remains After Glaxo’s OTC Transaction With Aspen" - Pink Sheet, 23 April, 2012..
Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica
GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.